-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target

Benzinga·12/22/2025 16:00:42
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.